Therapeutic success of HER2-DC1 vaccination in HER2+ BC supports the notion that targeting other oncodrivers employing the DC vaccine platform can have far-reaching beneficial effects in breast and other cancers dependent on oncodrivers, such as TNBC, which otherwise lacks effective therapeutic strategy. The gene discussed is ERBB2; the disease is breast cancer.